Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy

X
Trial Profile

A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CARE-MS-II
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 22 Apr 2021 Results of pooled data of CARE-MS studies (NCT00530348; NCT00548405; NCT00930553) presented at the 73rd Annual Meeting of the American Academy of Neurology.
    • 13 Sep 2020 Results (n=1216) of analysis assessing autoimmune adverse events from five clinical studies: NCT00050778, NCT00530348, NCT00548405, NCT00930553, NCT02255656 presented at the 8th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
    • 26 May 2020 Results presenting incidences of acute adverse events (AEs) reported during infusion and in the days following in the CARE-MS studies and postmarketing setting presented at the 6th Congress of the European Academy of Neurology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top